Managed Care Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
GlaxoSmithKline
Initial studies suggest that Lp-PLA2 inhibitors can block enzyme activity
October 9th, 2005
Lipoprotein-associated phospholipase A2 may be a marker of cardiovascular risk and potential therapeutic target. According to a report published in Expert Opinion on Investigational Drugs, "Although the clinical benefit of statins is well established, these agents reduce the risk of cardiovascular events by only 20-40%, and the residual risk for high-risk patients is considerable. The recognition of atherosclerosis as an inflammatory disease has opened the door to numerous complementary therapeutic approaches to further reduce risk and the overall burden of cardiovascular disease." C. Macphee and colleagues of GlaxoSmithKline...
Source: Managed Care Law Weekly (2005-10-09)
|
